Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC PeerVoice Heart & Lung Audio

Visit https://www.peervoice.com/HGH860 to view the entire programme with slides. After completing “Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC”, participants will be able to: Apply current evidence-based treatment guidelines in patients with molecular biomarker–positive non–small-cell lung cancer (NSCLC); Propose personalised treatment plans for patients with molecular biomarker–positive NSCLC; and Identify key clinical challenges encountered in the treatment of NSCLC, including next steps in patients without targetable driver mutations.